Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Luciana Simões Camara Leão"'
Autor:
Roberta Borges Silva, Luciana Simões Camara Leão, Virginia Kagure Wachira, Camile Giaretta Sachetti, Aurelina Aguiar de Lima, Cecília Menezes Farinasso, Betânia Leite, Daniela Fortunato Rêgo, Dalila Gomes Fernandes
Publikováno v:
BIS. Boletim do Instituto de Saúde. 20:114-124
Contexto: O gasto elevado com medicamentos biológicos ameaça a sustentabilidade dos serviços de saúde. O objetivo da presente re-visão rápida foi embasar a discussão da Política Nacional de Medi-camentos Biológicos no âmbito do Sistema Úni
Autor:
Betânia Leite, Camile Giaretta Sachetti, Luciana Simões Camara Leão, Aurelina Aguiar de Aguiar, Daniela Fortunato Rêgo, Lenilson Pereira Gonçalves, Dalila Fernandes Gomes, Roberta Borges Silva, Cecília Menezes Farinasso
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:29-30
IntroductionThe Department of Sciences and Technology (Decit) of the Brazilian Government has played a vital role in drafting of the National Policy for Biologic Medicines. Decit has provided methodological support to the working group, conducting a
Autor:
Luciana Simões Camara Leão, Erica Ell, Dalila Fernandes Gomes, Camile Giaretta Sachetti, Patrícia Couto, Daniela Fortunato Rêgo, Betânia Leite, Lenilson Gonçalvez
Publikováno v:
International Journal of Technology Assessment in Health Care. 34:47-48
Introduction:In 2017 the Brazilian Ministry of Health (BMH), through the Department of Science and Technology (DECIT) and in partnership with the Hospital Alemão Oswaldo Cruz (HAOC), financially supported research activities focused on health techno
Autor:
Dalila Fernandes Gomes, Aurelina Aguiar de Aguiar, Lenilson Pereira Gonçalves, Camile Giaretta Sachetti, Cecília Menezes Farinasso, Daniela Fortunato Rêgo, Luciana Simões Camara Leão, Betânia Leite, Roberta Borges Silva
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:30-30
IntroductionDue to the high judicialization rates which pressure the financing of biologic medicines by the Brazilian Unified Health System (Sistema Único de Saúde - SUS), it has been decided to formulate the National Policy for Biologic Medicines.